Vladimir Khavinson led the team that developed epitalon in St. Petersburg, Russia. The researchers who discovered epitalon were studying how short protein fragments might influence aging. His name is central to the story, but the published work involved several collaborators.
The discovery grew out of an older animal-tissue extract called epithalamin. Epitalon is a separate, manufactured molecule. That distinction matters when a decades-old study turns up in a conversation about today's prescription.
Who discovered epitalon, and what were they studying?
Khavinson's program studied peptides, short chains of amino acids, the building blocks of proteins. The broad question was whether these small chains could influence changes associated with aging.
One strand focused on the pineal gland, a small gland in the brain that makes melatonin. Melatonin is a hormone that helps signal the body's day-and-night rhythm. Researchers studied an animal pineal extract called epithalamin before developing the synthetic peptide.
The work became closely associated with the St. Petersburg Institute of Bioregulation and Gerontology. Gerontology means the study of aging; bioregulation refers to controlling biological processes. Khavinson founded the institute in 1992, according to the International Association of Gerontology and Geriatrics' official biography.
That institutional history helps explain why his name keeps appearing across the early papers. It also explains why epitalon's discovery belongs to a research program, rather than one isolated experiment.
From epithalamin to a four-amino-acid peptide
The practical advance was a defined synthetic molecule instead of an animal-tissue mixture. Epitalon contains four amino acids: alanine, glutamic acid, aspartic acid and glycine. Their abbreviated sequence is Ala-Glu-Asp-Gly, often shortened to AEDG. Epithalon is another spelling of epitalon and the name used in Promise's catalog.
A defined sequence gave researchers a specific substance to manufacture and test. It didn't make the older extract and the new peptide interchangeable.
The first-synthesis date has two versions, even within the FDA's own briefing. Its chemistry section says late 1980s, under Khavinson's direction. Its historical review says 1999, following a literature search. The latter account connects development to limited supplies of calf pineal tissue.
These accounts agree on the program's leader and the extract-to-peptide connection. They leave the exact first-synthesis year unsettled. The published papers provide firmer milestones than choosing one date without qualification.
The papers behind epitalon's reputation
A 2000 paper in Mechanisms of Ageing and Development tested synthetic epitalon in fruit flies. Its authors included Khavinson, D. M. Izmaylov, L. K. Obukhova and V. V. Malinin. The researchers reported longer adult lifespans after exposure during early development. This was animal evidence.
The better-known 2003 paper in Bulletin of Experimental Biology and Medicine came from Khavinson, I. E. Bondarev and A. A. Butyugov. They tested cultured human fetal fibroblasts, cells that help build connective tissue.
They reported activity of telomerase, an enzyme that rebuilds telomeres, the protective caps at chromosome ends. Chromosomes are bundles of genetic material that carry genes. The caps lengthened in the cultured cells. People weren't given epitalon in that experiment, and the result didn't establish longer human lives.
Human exposure appears in the record too. A 2002 eye-disease paper came from Khavinson and colleagues, including Svetlana Trofimova. They studied epitalon in people with damage to the retina, the light-sensitive tissue at the back of the eye.
Meanwhile, a 2003 study by Khavinson and Vyacheslav Morozov followed older adults given epithalamin and thymalin. Thymalin is an extract from the thymus, a gland involved in immune development. Those were extracts, rather than synthetic epitalon. The epitalon clinical trials guide separates these human studies and their limits.
Vladimir Khavinson's recognition in aging research
Khavinson also held an international leadership role in aging research. The association's July 2011 newsletter records his designation as chair of its European region. The European Council approved that appointment on April 16, 2011, in Bologna.
The following page lists him as European-region president for the 2011–2015 executive team. This is documented recognition by an aging-research organization. It isn't a clinical endorsement of epitalon or a finding about what the peptide does in patients.
A scientist's standing helps place the work in context. The experiments still have to answer their own questions, and later teams have to test whether the findings hold up.
What came of the discovery
Much of the foundational literature came from Khavinson's research network. A sustained program can build detailed knowledge of a molecule. It can also carry the same methods and assumptions from one study to the next.
Independent replication means another team repeats a finding. That matters because an effect should survive changes in who conducts the experiment and how it is measured.
Outside work predates 2025. In Aging, in 2022, Xue Yue and colleagues at Chinese and U.S. institutions studied epitalon in mouse egg cells outside the body. This broadened the research beyond the founding network. It didn't repeat the human-cell telomere experiment or test fertility treatment in people.
A 2025 Biogerontology paper by Sarah Al-Dulaimi and colleagues at Brunel University London reported telomere lengthening in cultured human cells. That paper has a published correction, linked from its PubMed record. It remains a laboratory result.
Independent laboratory work strengthens the case for further investigation. It doesn't settle human lifespan, lasting clinical benefit or long-term safety. The epitalon benefits review examines the outcome claims separately.
Where the discovery stands today
As of September 30, 2026, the day this article was written, epitalon has received an advisory recommendation for prescription compounding. On July 24, the Pharmacy Compounding Advisory Committee recommended adding epitalon free base and epitalon acetate to the 503A bulks list, an FDA ingredient list for certain prescription compounding. These are two chemical forms of the peptide. The FDA's meeting recording documents the recommendation.
The FDA meeting page explains that committee recommendations are nonbinding. The vote itself neither adds an ingredient to the list nor approves a finished medicine.
Epithalon will be dispensed as a compounded medication, which is different from an FDA-approved product: the formulation Promise will offer is not FDA-approved. Epithalon is coming soon to Promise — add me to the list. A licensed provider may still prescribe a compounded formulation where permitted; that decision is between you and your doctor.
What a prescription visit adds
At Promise, a licensed U.S. provider reviews every request; not everyone qualifies.
The visit connects the history to a particular person's health, medicines and goals. The provider decides whether prescribing is appropriate and sets the formulation, route and schedule. The epitalon dosage guide explains why published schedules don't establish one standard human injection course.
The original researchers weren't testing every formulation now offered by a pharmacy. Their papers cannot establish the identity, strength or storage needs of a particular dispensed product. Those details belong to the prescription and pharmacy label, alongside contact information for follow-up.
A prescription filled by a licensed U.S. compounding pharmacy also creates an accountable dispensing record and a place to direct medication questions. That accountability serves a different purpose from a laboratory finding. It supports a documented care process while the unanswered research questions remain.
